5-Amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

Name	AS1842856
Synonyms	CS-2538 AS1842856 AS 1842856 AS-1842856 5-Amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid 5-Amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 3-Quinolinecarboxylic acid, 5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-
CAS	836620-48-5

Molecular Formula	C18H22FN3O3
Molar Mass	347.38
Density	1.370±0.06 g/cm3(Predicted)
Boling Point	587.3±50.0 °C(Predicted)
Solubility	DMSO: 7.6 mg/mL (Need ultrasonic and warming)
pKa	6.47±0.50(Predicted)
Storage Condition	Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
In vitro study	AS1842856 inhibits foxo1-mediated transactivation by direct binding to foxo1. In HepG2 cells Transiently transfected with the Foxo1 expression vector, AS1842856 effectively inhibited foxo1-mediated promoter activity, a dose-dependent effect similar to that of insulin treatment. 0.1 μm AS1842856 inhibited 3% Foxo3a-and 20% Foxo4-mediated promoter activity, respectively. In contrast, foxo1-mediated promoter activity was reduced by 70%. Foxo1 inhibitor AS1842856 may inhibit the activity of endogenous G6Pase and PEPCK by reducing the mRNA levels of G6Pase and PEPCK, which may inhibit the production of glucose in Fao cells.
In vivo study	Oral administration of AS1842856 to db/db mutant mice with diabetes resulted in a significant decrease in fasting blood glucose by inhibiting liver gluconeogenesis-related genes. Normal mice after oral administration of AS1842856 has no such effect. Treatment with AS1842856 also inhibited the rise in blood glucose levels caused by injection of pyruvate (normal mice and db/db mice).

Last Update：2024-01-02 23:10:35

biological activity	AS1842856 is a cell permeable inhibitor that inhibits the transcriptional activity of Foxo1 with IC50 = 33 nM. AS1842856 binds directly to activated Foxo1, but does not bind to Foxo1 phosphorylated at ser256. AS1842856 can inhibit autophagy.
Target	TargetValue Foxo1 (In HepG2 cells) 33nM
Target	Value
Foxo1 (In HepG2 cells)	33nM
in vitro study	AS1842856 inhibits foxo1-mediated transactivation by direct binding to foxo1. In HepG2 cells Transiently transfected with the Foxo1 expression vector, AS1842856 effectively inhibited foxo1-mediated promoter activity, a dose-dependent effect similar to that of insulin treatment. 0.1 μm AS1842856 inhibited 3% Foxo3a-and 20% Foxo4-mediated promoter activity, respectively. In contrast, foxo1-mediated promoter activity was reduced by 70%. Foxo1 inhibitor AS1842856 may inhibit the activity of endogenous G6Pase and PEPCK by reducing the mRNA levels of G6Pase and PEPCK, which may inhibit the production of glucose in Fao cells.
in vivo study	The db/db mutant mice with diabetes mellitus were orally administered with AS1842856, through inhibition of liver gluconeogenesis-related genes, resulting in a significant decline in their fasting blood glucose values. Normal mice after oral administration of AS1842856 has no such effect. Treatment with AS1842856 also inhibited the rise in blood glucose levels caused by injection of pyruvate (normal mice and db/db mice).

Last Update：2024-04-10 22:29:15

Spot supply

Product Name: AS1842856 Visit Supplier Webpage Request for quotation
CAS: 836620-48-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409

Wechat: 18301782025

Spot supply

Product Name: AS1842856 Visit Supplier Webpage Request for quotation
CAS: 836620-48-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409

Wechat: 18301782025

View History

5-Amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid Request for Quotation